Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer

Data of a Pooled Analysis

Seeber, Andreas, MD, PhD*; Chahine, Georges, MD; Nasr, Fadi, MD; Dean, Andrew, MD; Miranova, Mira, MD; Jameson, Gayle, MD§; Robert, Nicholas, MD; Gastl, Guenther, MD*; Zwierzina, Heinz, MD*

doi: 10.1097/PPO.0000000000000358
Original Articles

Purpose Improvements in systemic treatment have led to a prolongation of survival and quality of life in patients with metastatic tumors in recent years. However, despite this improved standard of care, it is expected that the progression-free survival (PFS) for patients with refractory cancers will continue to decline over subsequent therapy lines. In those patients, studies and meta-analyses showed that treatment based on multiplatform molecular profiling (MMP) of tumor tissue may derive a clinical benefit. The aim of this study was to analyze if molecular-based therapy may prolong PFS compared with the PFS of the immediately prior therapy.

Methods We pooled clinical data of 140 patients treated within 3 recently conducted pilot studies and included an additional 21 patients who were treated within the ongoing ONCO-T-PROFILE program. The PFS of the molecular-based treatment was compared with the PFS of the previous therapy using Kaplan-Meier curves.

Results In heavily pretreated cancer patients, the PFS could be significantly improved using molecular-based treatment options (120.0 vs. 89.5 days). More than 50% of patients showed a clinical benefit from MMP-guided therapy as defined by a PFS ratio of 1.3 or greater.

Conclusions We conclude that pretreated cancer patients can benefit from incorporation of molecular profiling, as demonstrated by not only an increase of the PFS ratio but also PFS. Further randomized trials in specific tumor subtypes may help establish specific patient populations who might benefit most from MMP guidance.

From the *Department of Haematology and Oncology, Innsbruck Medical University, Innsbruck, Austria;

Hôtel-Dieu de France, Centre Hospitalier de l'Université Saint-Joseph de Beyrouth, Beirut, Lebanon;

St John of God Hospital, Subiaco, Western Australia, Australia;

§Virginia G Piper Cancer Center—Clinical Trials, Scottsdale Healthcare, Scottsdale, AZ; and

Virginia Cancer Specialists, Fairfax, VA.

Conflicts of Interest and Source of Funding: A.S., G.G., and H.Z. served as consultant for Caris Life Sciences. For the remaining authors, none were declared.

Reprints: Andreas Seeber, MD, PhD, Department of Haematology and Oncology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria. E-mail:

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.